SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/14/22 CASI Pharmaceuticals, Inc. 10-Q 9/30/22 74:7.2M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 1.67M 2: EX-10.1 Material Contract HTML 289K 3: EX-31.1 Certification -- §302 - SOA'02 HTML 25K 4: EX-31.2 Certification -- §302 - SOA'02 HTML 26K 5: EX-32.1 Certification -- §906 - SOA'02 HTML 22K 6: EX-32.2 Certification -- §906 - SOA'02 HTML 23K 12: R1 Document and Entity Information HTML 74K 13: R2 Unaudited Condensed Consolidated Balance Sheets HTML 126K 14: R3 Unaudited Condensed Consolidated Balance Sheets HTML 43K (Parenthetical) 15: R4 Unaudited Condensed Consolidated Statements of HTML 147K Operations and Comprehensive Loss 16: R5 Unaudited Condensed Consolidated Statements of HTML 81K Stockholders' Equity 17: R6 Unaudited Condensed Consolidated Statements of HTML 141K Cash Flows 18: R7 Description of Business HTML 27K 19: R8 License and Distribution Agreements HTML 41K 20: R9 Summary of Significant Accounting Policies HTML 26K 21: R10 Revenue Related Information HTML 25K 22: R11 Investment in Equity Securities, at Fair Value and HTML 192K Long-term Investments 23: R12 Inventories HTML 22K 24: R13 Property, Plant and Equipment HTML 41K 25: R14 Leases HTML 63K 26: R15 Accrued and Other Current Liabilities, and Other HTML 52K Liabilities 27: R16 Bank Borrowings HTML 21K 28: R17 Redeemable Noncontrolling Interest HTML 38K 29: R18 Stockholders' Equity HTML 31K 30: R19 Net Loss Per Share HTML 58K 31: R20 Stock-Based Compensation HTML 38K 32: R21 Income Taxes HTML 25K 33: R22 Fair Value Measurements HTML 106K 34: R23 Related Party Transactions HTML 24K 35: R24 Commitments and Contingencies HTML 27K 36: R25 Subsequent Events HTML 23K 37: R26 Summary of Significant Accounting Policies HTML 31K (Policies) 38: R27 Investment in Equity Securities, at Fair Value and HTML 189K Long-term Investments (Tables) 39: R28 Property, Plant and Equipment (Tables) HTML 39K 40: R29 Leases (Tables) HTML 63K 41: R30 Accrued and Other Current Liabilities, and Other HTML 51K Liabilities (Tables) 42: R31 Redeemable Noncontrolling Interest (Tables) HTML 37K 43: R32 Net Loss Per Share (Tables) HTML 56K 44: R33 Stock-Based Compensation (Tables) HTML 36K 45: R34 Fair Value Measurements (Tables) HTML 99K 46: R35 Description of Business (Details) HTML 30K 47: R36 License and Distribution Agreements (Details) HTML 112K 48: R37 Investment in Equity Securities, at Fair Value and HTML 32K Long-term Investments - Summary of Investments (Details) 49: R38 Investment in Equity Securities, at Fair Value and HTML 58K Long-term Investments - Summary of Long-term investments (Details) 50: R39 Investment in Equity Securities, at Fair Value and HTML 57K Long-term Investments (Details) 51: R40 Inventories (Details) HTML 25K 52: R41 Property, Plant and Equipment (Details) HTML 36K 53: R42 Leases - (Details) HTML 39K 54: R43 Leases - Right of Use Assets and Liabilities HTML 36K (Details) 55: R44 Leases - Supplemental Cash Flow (Details) HTML 25K 56: R45 Leases - Future Undiscounted Cash Flows (Details) HTML 38K 57: R46 Accrued and Other Current Liabilities, and Other HTML 50K Liabilities (Details) 58: R47 Bank Borrowings (Details) HTML 36K 59: R48 Redeemable Noncontrolling Interest - Changes in HTML 30K Redeemable Noncontrolling Interest (Details) 60: R49 Stockholders' Equity (Details) HTML 51K 61: R50 Net Loss Per Share (Details) HTML 24K 62: R51 Net Loss Per Share - Basic and diluted net loss HTML 54K per share computation (Details) 63: R52 Stock-Based Compensation - Compensation Expense HTML 29K (Details) 64: R53 Income Taxes (Details) HTML 22K 65: R54 Fair Value Measurements - Financial and HTML 47K Non-Financial Assets and Liabilities (Details) 66: R55 Fair Value Measurements (Details) HTML 31K 67: R56 Related Party Transactions (Details) HTML 33K 68: R57 Commitments and Contingencies (Details) HTML 47K 69: R58 Subsequent Event (Details) HTML 25K 72: XML IDEA XML File -- Filing Summary XML 132K 70: XML XBRL Instance -- casi-20220930x10q_htm XML 1.82M 71: EXCEL IDEA Workbook of Financial Reports XLSX 117K 8: EX-101.CAL XBRL Calculations -- casi-20220930_cal XML 163K 9: EX-101.DEF XBRL Definitions -- casi-20220930_def XML 475K 10: EX-101.LAB XBRL Labels -- casi-20220930_lab XML 850K 11: EX-101.PRE XBRL Presentations -- casi-20220930_pre XML 719K 7: EX-101.SCH XBRL Schema -- casi-20220930 XSD 158K 73: JSON XBRL Instance as JSON Data -- MetaLinks 332± 503K 74: ZIP XBRL Zipped Folder -- 0001558370-22-017615-xbrl Zip 320K
Exhibit 32.2
CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Larry (Wei) Zhang, as Principal Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report. |
The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.
| |
Date: November 14, 2022 | |
| |
| Principal Financial Officer |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 11/14/22 | None on these Dates | ||
For Period end: | 9/30/22 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. (DE) 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 3/21/23 CASI Pharmaceuticals, Inc. (DE) S-8 POS 3/21/23 3:172K Toppan Merrill/FA 2/14/23 CASI Pharmaceuticals, Inc. 424B3 1:1.7M Toppan Merrill/FA 2/14/23 CASI Pharmaceuticals, Inc. (DE) DEF 14A 3/20/23 1:1.7M Toppan Merrill/FA 2/09/23 CASI Pharmaceuticals, Inc. F-4/A 1:924K Toppan Merrill/FA 1/31/23 CASI Pharmaceuticals, Inc. F-4 22:2.7M Toppan Merrill/FA |